GS7.DE Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 liep. 2022 @ 18:35):

Stats
Šios dienos apimtis	290 930
Vidutinė apimtis	0
Rinkos kapitalizacija	0.00
EPS	€0.230 ( 2022-06-29 )
Last Dividend	€0.163 ( 2022-08-18 )
Next Dividend	€0 ( N/A )
P/E	17.31
ATR14	€0 (0.00%)

GSK plc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

GSK plc Finansinės ataskaitos

Annual	2021
Pajamos:	€34.11B
Bruto pelnas:	€22.51B (65.99 %)
EPS:	€1.102

FY	2021
Pajamos:	€34.11B
Bruto pelnas:	€22.51B (65.99 %)
EPS:	€1.102

FY	2020
Pajamos:	€34.10B
Bruto pelnas:	€22.40B (65.68 %)
EPS:	€1.426

FY	2019
Pajamos:	€33.75B
Bruto pelnas:	€21.89B (64.85 %)
EPS:	€1.158

Financial Reports:

No articles found.

GSK plc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0.163 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

GSK plc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.49 - good (84.92%) | Divividend Growth Potential Score: 4.55 - Potential for dividend initiation, but uncertain (9.01%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.140	2004-02-18
Last Dividend	€0.163	2022-08-18
Next Dividend	€0	N/A
Payout Date	2022-10-06
Next Payout Date	N/A
# dividends	75	--
Total Paid Out	€12.75	--
Avg. Dividend % Per Year	0.00%	--
Score	4.21	--
Div. Sustainability Score	8.49
Div.Growth Potential Score	4.55
Div. Directional Score	6.52	--

Next Divdend (Est)
(2024-06-28)

€0 Estimate 0.00 %

Dividend Stability

0.19 Bad

Dividend Score

4.21

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
VVD.DE	Ex Dividend Knight	2023-05-09	Annually	0.00%
EOAN.DE	Ex Dividend Junior	2023-05-18	Annually	0.00%
OHB.DE	Ex Dividend Junior	2023-05-26	Annually	0.00%
AHC.DE	Ex Dividend Knight	2023-09-15	Quarterly	0.00%
GUI.DE	Ex Dividend Knight	2023-08-24	Semi-Annually	0.00%
RIO1.DE	Ex Dividend Knight	2023-08-10	Semi-Annually	0.00%
BNR.DE	Ex Dividend Knight	2023-06-16	Annually	0.00%
ITU.DE	Ex Dividend Knight	2023-10-06	Quarterly	0.00%
TA1.DE	Ex Dividend Knight	2023-06-12	Annually	0.00%
DAM.DE	Ex Dividend Knight	2023-05-10	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.149	1.500	7.01	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0644	1.200	7.85	9.42	[0 - 0.3]
returnOnEquityTTM	0.344	1.500	7.29	10.00	[0.1 - 1]
payoutRatioTTM	0.785	-1.000	2.15	-2.15	[0 - 1]
currentRatioTTM	0.789	0.800	-1.055	-0.844	[1 - 3]
quickRatioTTM	0.183	0.800	-3.63	-2.90	[0.8 - 2.5]
cashRatioTTM	0.181	1.500	-0.108	-0.162	[0.2 - 2]
debtRatioTTM	0.306	-1.500	4.91	-7.36	[0 - 0.6]
interestCoverageTTM	7.03	1.000	8.51	8.51	[3 - 30]
operatingCashFlowPerShareTTM	1.998	2.00	9.33	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.261	2.00	9.37	10.00	[0 - 20]
debtEquityRatioTTM	1.606	-1.500	3.58	-5.37	[0 - 2.5]
grossProfitMarginTTM	0.660	1.000	2.34	2.34	[0.2 - 0.8]
operatingProfitMarginTTM	0.162	1.000	8.77	8.77	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.329	1.000	9.28	9.28	[0.2 - 2]
assetTurnoverTTM	0.431	0.800	-0.458	-0.367	[0.5 - 2]
Total Score				8.49

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.76	1.000	8.71	0	[1 - 100]
returnOnEquityTTM	0.344	2.50	8.26	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.261	2.00	9.58	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.998	2.00	9.33	10.00	[0 - 30]
payoutRatioTTM	0.785	1.500	2.15	-2.15	[0 - 1]
pegRatioTTM	0.188	1.500	-2.08	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.233	1.000	6.67	0	[0.1 - 0.5]
Total Score				4.55

GSK plc

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.